These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33242709)

  • 21. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
    Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
    Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells.
    Panya A; Thepmalee C; Sawasdee N; Sujjitjoon J; Phanthaphol N; Junking M; Wongkham S; Yenchitsomanus PT
    Cancer Immunol Immunother; 2018 Oct; 67(10):1579-1588. PubMed ID: 30056600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer.
    Somboonpatarakun C; Phanthaphol N; Suwanchiwasiri K; Ramwarungkura B; Yuti P; Poungvarin N; Thuwajit P; Junking M; Yenchitsomanus PT
    Int Immunopharmacol; 2024 Mar; 129():111631. PubMed ID: 38359664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the Effector Functions of Vδ2 γδ T Cells and NK Cells against Cholangiocarcinoma Cells.
    Kulma I; Na-Bangchang K; Carvallo Herrera A; Ndubuisi IT; Iwasaki M; Tomono H; Morita CT; Okamura H; Mukae H; Tanaka Y
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
    Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
    Stoiber S; Cadilha BL; Benmebarek MR; Lesch S; Endres S; Kobold S
    Cells; 2019 May; 8(5):. PubMed ID: 31108883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of the C-terminus of CD6 to a chimeric antigen receptor enhances cytotoxicity and does not compromise expression.
    Breuning J; Philip B; Brown MH
    Immunology; 2019 Feb; 156(2):130-135. PubMed ID: 30300924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns.
    Jiraviriyakul A; Songjang W; Kaewthet P; Tanawatkitichai P; Bayan P; Pongcharoen S
    World J Gastroenterol; 2019 Aug; 25(29):3941-3955. PubMed ID: 31413529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strong expression of CD133 is associated with increased cholangiocarcinoma progression.
    Leelawat K; Thongtawee T; Narong S; Subwongcharoen S; Treepongkaruna SA
    World J Gastroenterol; 2011 Mar; 17(9):1192-8. PubMed ID: 21448425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
    Carpenito C; Milone MC; Hassan R; Simonet JC; Lakhal M; Suhoski MM; Varela-Rohena A; Haines KM; Heitjan DF; Albelda SM; Carroll RG; Riley JL; Pastan I; June CH
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3360-5. PubMed ID: 19211796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
    Till BG; Jensen MC; Wang J; Qian X; Gopal AK; Maloney DG; Lindgren CG; Lin Y; Pagel JM; Budde LE; Raubitschek A; Forman SJ; Greenberg PD; Riddell SR; Press OW
    Blood; 2012 Apr; 119(17):3940-50. PubMed ID: 22308288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
    Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
    Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.